Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Ferrandina, Gabriella ^a   Ranelletti, Franco O ^a   Martinelli, Enrica ^a   Paglia, Amelia ^a   Zannoni, Gian Franco ^a   Scambia, Giovanni ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 2; PACLITAXEL; PARAFFIN; PLATINUM DERIVATIVE; POLYCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OVARIECTOMY; OVARY CANCER; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE 2; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM; SURVIVAL RATE;

EID: 33747020100     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-182     Document Type: Article

References (37)

1. Lundis SH, Murray T, Bolden S, Wingo PA: Cancer Statistics. CA Cancer J Clin 1998, 48:6-13.
2. Hoskins WJ, Perez CA, Young RC: Principles and Practice of Gynecologic Oncology. Philadelphia. PA: Lippincott Williams and Wilkins; 2000:1005-1007.
3. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996, 56:4881-4886.
4. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F: A comparative study of p53 mutations, protein accumulation, and response to cisplatin based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996, 56:689-693.
5. Murata T, Haisa M, Uetsuka H, Nobuhisha T, Ookawa T, Tabuchi Y, Shirakawa Y, Yamatsuji T, Matsuoka J, Nishiyama M, Tanaka N, Naomoto Y: Molecular mechanisms of chemoresistance to cisplatin in ovarian cancer cells. Int J Mol Med 2004, 13(6):865-868.
6. Ferrandina G, Fagotti A, Salerno G, Natali PG, Mottolese M, Maneschi F, De Pasqua A, Benedetti Panici P, Mancuso S, Scambia G: P53 over-expression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer 1999, 81:733-740.
7. Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti M, Scambia G, Ferrandina G, Fagotti A, Mangioni C, Lucchini V, Vecchione F, Bolis G, Scarfone G, Zunino F: p53 status and response to platinum/paclitaxel based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000, 18:3936-3945.
8. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996, 2:72-79.
9. La Casse EC, Baird S, Korneluk RG, MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998, 17:3257-3259.
10. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Zunino F, Daidone MG: Expression of the antipoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002, 59:1406-1412.
11. Chandrasekharan NV, Simmons DL: The cyclooxygenases. Genome Biology 2004, 5:241-247.
12. Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti FO, Scambia G: Increased cyclooxygenase-2 (COX-2) eatpression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002, 13:1205-1211.
13. Ferrandina G, Ranelletti FO, Legge F, Gessi M, Salutari V, Distefano MG, Lauriola L, Zannoni GF, Martinelli E, Scambia G: Prognostic role of the ratio between cyclooxygenase-2 (COX-2) in tumor and stroma, compartments in cervical cancer. Clin Cancer Res 2004, 10(9):3117-3123.
14. Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi M, Legge F, Maggiano N, Mancuso S, Capelli A, Scambia G, Ranelletti FO: Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 2002, 20:973-981.
15. Altundag O, Altundag K, Morandi P, Gunduz M: Cyclooxygenase-2 inhibitor and cisplatin combination as radiosensitizer in the treatment of head and neck cancer patients. Ann Oncol 2004, 15:1444-1445.
16. Awara WM, El-Sisi AZ, El-Sayad ME, Goda AE: The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally induced mammary tumor: does celecoxib enhance the anti-tumor activity of doxorubicin? Pharmacol Res 2004, 50:487-498.
17. World Health Organization: WHO handbook for reporting results of cancer treatment. WHO, Geneva, Offset publication no.48; 1979:16-21.
18. Kaplan E, Meyer P: Non parametric estimation from incomplete observations. J Am Statist Association 1958, 53:457-481.
19. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966, 50:163-170.
20. Raspollini MR, Amunni G, Villanucci A, Boddi V, Baroni G, Taddei A, Taddei GL: Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol 2004, 92(3):806-812.
21. Liu XH, Yao S, Kirschenbaum A, Levine AC: NS-398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCap cells. Cancer Res 1998, 58:4245-4249.
22. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC: Inhibition of cyclooxyenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urology 2000, 164:820-825.
23. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R: Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999, 18:315-324.
24. Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T, Yoshimoto T: Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenase 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta 1999, 1438:120-130.
25. Choi EM, Heo JI, Oh JI, Kim YM, Ha KS, Kim JI, Han JA: COX-2 regulates p53 activity and inhibits DNA damage-induced apoptosis. Biochem Biophys Res Commun 2005, 328(4):1107-1112.
26. Corcoran CA, He Q, Huang Y, Sheikh MS: Cycloxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis. Oncogene 2005, 24:1634-1640.
27. Erkinheimo TL, Lassus H, Finne P, van Rees BP, Leminen A. Ylikorkala O, Baglund C, Butzow R, Ristimaki A: Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res 2004, 10(2):538-545.
28. Shigemasa K, Tian X, Gu L, Shiroyama Y, Nagai N, Ohama K: Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int J Oncol 2003, 22:99-105.
29. Ali-Fehmi R, Che M, Khalifeh I, Malone JM, Morris R, Lawrence WD, Munkarah AR: The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 2003, 98(7):1423-1429.
30. Jordan MA, Wilson L: Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998, 10:123-130.
31. Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli E, Ferrandina G, Gallo D, Ranelletti FO, Scambia G: Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol 2003, 64:51-58.
32. Subbamaraiah K, Marmo TP, Dixon DA, Dannemberg AJ: Regulation of Cyclooxygenase-2 mRNA stability by taxanes. J Biol Chem 2003, 278(39):37637-37647.
33. Hida T, Kozaki K, Ito H, Miyaishi O, Tatematsu Y, Suzuki T, Matsuo Y, Sugiura T, Ogawa M, Takahashi T, Takahashi T: Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase-2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res 2002, 8:2443-2447.
34. Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP: Increased endothelial uptake of paclitaxell as a potential mechanism for its antiangiogenic effects: potentiation by COX-2 inhibition. Int J Cancer 2005, 113:490-498.
35. Dandekar DS, Lopez M, Carey RI, Lokeshwar BL: Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 2005, 11(3):484-492.
36. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA, Yankelevitz DF, Subbamaraiah K, Pasmantier MW, Dannemberg AJ: Celecoxib, a selective cyclooxygenase-2 inhibitor, enhance the response to preoperative paclitaxel and carboplatin in early stage non small cell lung cancer. J Clin Oncol 2003, 21(14):2645-2650.
37. Altorki NK, Port JL, Zhang F, Goliijanin D, Thaler AJ, Duffield-Lilico AJ, Subbamaraiah K, Dannemberg AJ: Chemotherapy induces the expression of cyclooxygenase-2 in non small cell lung cancer. Clin Cancer Res 2005, 11:4191-4197.